For the Inventor, By the Inventor

Enter assignee name

Mountain View, CA, United States of America

Sanbio, Inc.

Calculating rank

USPTO Granted Patents = 38

% Expired Patents = 7.9

CIPO Patents = 2

EPO Patents = 19

Forward Citations = 203

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Casey Christopher Case (13 out of 40 patents)

Mari Dezawa (10 out of 28 patents)

Hajime Sawada (8 out of 8 patents)

4. Masahiko Takano (8 out of 8 patents)

5. Irina Aizman (7 out of 7 patents)

6. Hiroshi Kanno (7 out of 81 patents)

7. Mo Dao (5 out of 5 patents)

8. Aline Betancourt (4 out of 6 patents)

9. Ciara C Tate (4 out of 5 patents)

10. Damien Bates (2 out of 2 patents)

11. Toru Kawanishi (2 out of 3 patents)

12. Cesar V Borlongan (2 out of 4 patents)

13. Monique A Dao (2 out of 3 patents)

14. Noriyuki Kuno (2 out of 2 patents)

15. Keita Mori (2 out of 2 patents)

Core Competencies:

Stem Cell Culture

Cell Delivery System

Angiogenesis

Neural Regeneration

Biologically Active Mixtures

Peripheral Immune Function

CNS Disorders

Neuronal Progenitor Cells

FGF2 Isoforms

Traumatic Brain Injury

Retinal Degeneration

38 patents: Sort by Forward Citations

1. 12553033 - Medium, methods, cells and secreted factors for stem cell culture and therapy (2026-02-17),

2. RE50635 - Neural regenerating cells with alterations in DNA methylation (2025-10-14),

3. 12357761 - Cell delivery system and methods of operation thereof (2025-07-15),

4. 12171787 - Methods and compositions for modulating angiogenesis and vasculogenesis (2024-12-24),

5. 12121544 - Cell therapies and methods of treatment for small-volume stroke (2024-10-22),

6. 11946072 - Medium, methods, cells and secreted factors for stem cell culture and therapy (2024-04-02),

7. 11903972 - Methods and compositions for modulating peripheral immune function (2024-02-20),

8. 11512284 - Neural precursor cells expressing exogenous Notch intracellular domain (2022-11-29),

9. 11439761 - Cell delivery system and methods of operation thereof (2022-09-13),

10. 11406685 - Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of FGF2 isoforms (2022-08-09),

11. 11124771 - MSC growth predictor assays (2021-09-21),

12. 11046929 - Induction medium and methods for stem cell culture and therapy (2021-06-29),

13. 10702554 - Extracellular matrix from pluripotent cells (2020-07-07),

14. 10653724 - Extracellular matrix from pluripotent cells (2020-05-19),

15. 10626389 - Methods and compositions for modulation of migration of neurogenic cells (2020-04-21),

Company Overview

Sanbio, Inc. is a biotechnology company based in Mountain View, California, specializing in the development of advanced regenerative medicine therapies. The organization focuses on harnessing the power of cell-based treatments to address a variety of medical conditions, particularly in the fields of neurology and orthopedics. By leveraging innovative research and technology, Sanbio aims to improve patient outcomes and enhance the quality of life for individuals suffering from debilitating diseases and injuries.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

38 Patents

#86 in Mountain View, CA

#2,133 in California

#9,035 in US

#17,870 in the World

Mountain View, CA, United States of America

Sanbio, Inc.

Forward Citations = 203

26 inventors:

Casey Christopher Case (13 out of 40 patents)

Mari Dezawa (10 out of 28 patents)

Hajime Sawada (8 out of 8 patents)

4. Masahiko Takano (8 out of 8 patents)

5. Irina Aizman (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sanbio, Inc.. Retrieved from https://idiyas.com/company/sanbio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…